Genetic studies in chronic kidney disease: Interpretation and clinical applicability

Journal of Nephrology

Volumn 25, Issue 6, 2012, Pages 851-864

  Witasp, Anna ^a   Nordfors, Louise ^a   Carrero, Juan Jesus ^a   Luttropp, Karin ^a   Lindholm, Bengt ^a   Schalling, Martin ^a   Stenvinkel, Peter ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Chronic kidney disease; Epidemiology; Genetics

Indexed keywords

ATENOLOL; CHEMOKINE RECEPTOR CCR5; DIPEPTIDYL CARBOXYPEPTIDASE; ENALAPRIL; GLUTATHIONE TRANSFERASE M1; INTERLEUKIN 6 RECEPTOR;

CC CHEMOKINE RECEPTOR 5 GENE; CHRONIC KIDNEY DISEASE; DIALYSIS; DRUG RESPONSE; DRUG TARGETING; GENE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; GENOTYPING TECHNIQUE; GLUTATHIONE TRANSFERASE M1 GENE; HARDY WEINBERG DISTRIBUTION LAW; HUMAN; INTERLEUKIN 6 RECEPTOR GENE; INTERMETHOD COMPARISON; LIFESTYLE MODIFICATION; NUTRITIONAL ASSESSMENT; OUTCOME ASSESSMENT; PHARMACOGENETICS; PREDICTION; QUALITY CONTROL; QUANTITATIVE ANALYSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL ANALYSIS; THERAPY EFFECT;

ANIMALS; DECISION SUPPORT TECHNIQUES; GENETIC ASSOCIATION STUDIES; GENETIC COUNSELING; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; INDIVIDUALIZED MEDICINE; PHARMACOGENETICS; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC; REPRODUCIBILITY OF RESULTS; RISK FACTORS;

EID: 84870598898     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/jn.5000216     Document Type: Review

References (91)

1. Hardy J, Singleton A. Genomewide association studies and human disease. N Engl J Med. 2009;360(17):1759-1768.
2. Lander ES. Initial impact of the sequencing of the human genome. Nature. 2011;470(7333):187-197.
3. McKnight AJ, Currie D, Maxwell AP. Unravelling the genetic basis of renal diseases; from single gene to multifactorial disorders. J Pathol. 2010;220(2):198-216.
4. Chambers JC, Zhang W, Lord GM, et al. Genetic loci influencing kidney function and chronic kidney disease. Nat Genet. 2010;42(5):373-375.
5. Kottgen A, Kao WH, Hwang SJ, et al. Genome-wide association study for renal traits in the Framingham Heart and Atherosclerosis Risk in Communities Studies. BMC Med Genet. 2008;9(1):49.
6. Collins AJ, Foley RN, Chavers B, et al. United States Renal Data System 2011 annual data report: atlas of chronic kidney disease & end-stage renal disease in the United States. Am J Kidney Dis. 2012;59(Suppl 1):A7, e1-e420.
7. Green ED, Guyer MS, Green ED, Guyer MS, Manolio TA, Peterson JL; National Human Genome Research Institute. Charting a course for genomic medicine from base pairs to bedside. Nature. 2011;470(7333):204-213.
8. Nordfors L, Luttropp K, Carrero JJ, et al. Genetic studies in chronic kidney disease: basic concepts. J Nephrol. 2012;25(2):141-149.
9. Attia J, Ioannidis JP, Thakkinstian A, et al. How to use an article about genetic association: C: what are the results and will they help me in caring for my patients? JAMA. 2009;301(3):304-308.
10. Attia J, Ioannidis JP, Thakkinstian A, et al. How to use an article about genetic association: B: are the results of the study valid? JAMA. 2009;301(2):191-197.
11. Hunter DJ, Kraft P. Drinking from the fire hose: statistical issues in genome wide association studies. N Engl J Med. 2007;357(5):436-439.
12. van Stralen KJ, Dekker FW, Zoccali C, Jager KJ. Casecontrol studies: an efficient observational study design. Nephron Clin Pract. 2010;114(1):c1-c4.
13. Böger CA, Heid IM. Chronic kidney disease: novel insights from genome-wide association studies. Kidney Blood Press Res. 2011;34(4):225-234.
14. Köttgen A, Pattaro C, Böger CA, et al. New loci associated with kidney function and chronic kidney disease. Nat Genet. 2010;42(5):376-384.
15. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164(6):659-663.
16. Bash LD, Coresh J, Köttgen A, et al. Defining incident chronic kidney disease in the research setting: the ARIC Study. Am J Epidemiol. 2009;170(4):414-424.
17. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298 (17):2038-2047.
18. Fouque D, Kalantar-Zadeh K, Kopple J, et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int. 2008;73(4):391-398.
19. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13): 1296-1305.
20. Phen X. Consensus measures for phenotypes and exposures (PhenX) [website home page]. Available at: https://www.phenx.org/. Accessed March 12, 2012.
21. Huentelman MJ, Craig DW, Shieh AD, et al. SNiPer: improved SNP genotype calling for Affymetrix 10K GeneChip microarray data. BMC Genomics. 2005;6(1):149.
22. Finner H, Strassburger K, Heid IM, et al. How to link call rate and p-values for Hardy-Weinberg equilibrium as measures of genome-wide SNP data quality. Stat Med. 2010;29(22): 2347-2358.
23. Pongpanich M, Sullivan PF, Tzeng JY. A quality control algorithm for filtering SNPs in genome-wide association studies. Bioinformatics. 2010;26(14):1731-1737.
24. Hoggart CJ, Clark TG, De Iorio M, Whittaker JC, Balding DJ. Genome-wide significance for dense SNP and resequencing data. Genet Epidemiol. 2008;32(2):179-185.
25. McCarthy MI, Abecasis GR, Cardon LR, et al. Genomewide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet. 2008;9(5): 356-369.
26. König IR, Nsengimana J, Papachristou C, Simonson MA, Wang K, Weisburd JA. Multiple testing in high-throughput sequence data: experiences from Group 8 of Genetic Analysis Workshop 17. Genet Epidemiol. 2011;35(S1)(Suppl 1):S61-S66.
27. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet. 2006;38(8):904-909.
28. van Stralen KJ, Dekker FW, Zoccali C, Jager KJ. Confounding. Nephron Clin Pract. 2010;116(2):c143-c147.
29. Verduijn M, Jager KJ, Zoccali C, Dekker FW. Genetic association studies: discovery of the genetic basis of renal disease. Nephron Clin Pract. 2011;119(3):c236-c239.
30. Chanock SJ, Manolio T, Boehnke M, et al; NCI-NHGRI Working Group on Replication in Association Studies. Replicating genotype-phenotype associations. Nature. 2007;447(7145): 655-660.
31. Couser W. Revisions to instructions to JASN authors regarding articles reporting studies using DNA arrays, DNA polymorphisms, and randomized controlled clinical trials. J Am Soc Nephrol. 2003;14(10):2686-2687.
32. Strengthening the Reporting of Genetic Associations [website home page]. Available at: http://www.strega-statement.org/.Accessed July 9, 2012.
33. Tripepi G, Jager KJ, Dekker FW, Wanner C, Zoccali C. Measures of effect: relative risks, odds ratios, risk difference, and 'number needed to treat'. Kidney Int. 2007;72(7):789-791.
34. Hindorff LA, Sethupathy P, Junkins HA, et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci USA. 2009;106(23):9362-9367.
35. Ware JH. The limitations of risk factors as prognostic tools. N Engl J Med. 2006;355(25):2615-2617.
36. Maher B. Personal genomes: the case of the missing heritability. Nature. 2008;456(7218):18-21.
37. Yang Q, Khoury MJ, Friedman J, Little J, Flanders WD. How many genes underlie the occurrence of common complex diseases in the population? Int J Epidemiol. 2005;34(5): 1129-1137.
38. Kathiresan S, Melander O, Anevski D, et al. Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med. 2008;358(12):1240-1249.
39. Kraft P, Wacholder S, Cornelis MC, et al. Beyond odds ratios: communicating disease risk based on genetic profiles. Nat Rev Genet. 2009;10(4):264-269.
40. Collins FS, Guyer MS, Charkravarti A. Variations on a theme: cataloging human DNA sequence variation. Science. 1997;278(5343):1580-1581.
41. Reich DE, Lander ES. On the allelic spectrum of human disease. Trends Genet. 2001;17(9):502-510.
42. Ioannidis JP, Thomas G, Daly MJ. Validating, augmenting and refining genome-wide association signals. Nat Rev Genet. 2009;10(5):318-329.
43. International HapMap Consortium. A haplotype map of the human genome. Nature. 2005;437(7063):1299-1320.
44. Marchini J, Howie B, Myers S, McVean G, Donnelly P. A new multipoint method for genome-wide association studies by imputation of genotypes. Nat Genet. 2007;39(7): 906-913.
45. Casals F, Idaghdour Y, Hussin J, Awadalla P. Next-generation sequencing approaches for genetic mapping of complex diseases. J Neuroimmunol. 2012;248(1-2):10-22.
46. Metzker ML. Sequencing technologies: the next generation. Nat Rev Genet. 2010;11(1):31-46.
47. Tonelli M, Wiebe N, Culleton B, et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol. 2006;17(7):2034-2047.
48. Jager KJ, Stel VS, Zoccali C, Wanner C, Dekker FW. The issue of studying the effect of interventions in renal replacement therapy: to what extent may we be deceived by selection and competing risk? Nephrol Dial Transplant. 2010;25(12):3836-3839.
49. Dietz HC. New therapeutic approaches to mendelian disorders. N Engl J Med. 2010;363(9):852-863.
50. Robson M, Offit K. Clinical practice: management of an inherited predisposition to breast cancer. N Engl J Med. 2007;357(2):154-162.
51. Prior TW; Professional Practice and Guidelines Committee. Carrier screening for spinal muscular atrophy. Genet Med. 2008;10(11):840-842.
52. Miller DT, Adam MP, Aradhya S, et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet. 2010;86(5):749-764.
53. Freedman BI, Hicks PJ, Bostrom MA, et al. Polymorphisms in the non-muscle myosin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African Americans. Kidney Int. 2009;75(7):736-745.
54. Kao WH, Klag MJ, Meoni LA, et al. Family Investigation of Nephropathy and Diabetes Research Group. MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet. 2008;40(10):1185-1192.
55. Freedman BI, Kopp JB, Langefeld CD, et al. The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans. J Am Soc Nephrol. 2010;21(9):1422-1426.
56. Genovese G, Tonna SJ, Knob AU, et al. A risk allele for focal segmental glomerulosclerosis in African Americans is located within a region containing APOL1 and MYH9. Kidney Int. 2010;78(7):698-704.
57. Tzur S, Rosset S, Shemer R, et al. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet. 2010;128(3):345-350.
58. Drawz PE, Sedor JR. The genetics of common kidney disease: a pathway toward clinical relevance. Nat Rev Nephrol. 2011;7(8):458-468.
59. Frueh FW, Amur S, Mummaneni P, et al. Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use. Pharmacotherapy. 2008;28(8):992-998.
60. Wienkers LC, Heath TG. Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov. 2005;4(10):825-833.
61. Molanaei H, Carrero JJ, Heimbürger O, et al. Influence of the CYP2D6 polymorphism and hemodialysis on codeine disposition in patients with end-stage renal disease. Eur J Clin Pharmacol. 2010;66(3):269-273.
62. van Essen GG, Rensma PL, de Zeeuw D, et al. Association between angiotensin-converting-enzyme gene polymorphism and failure of renoprotective therapy. Lancet. 1996;347(8994): 94-95.
63. Muntinghe FL, Verduijn M, Zuurman MW, et al. CCR5 deletion protects against inflammation-associated mortality in dialysis patients. J Am Soc Nephrol. 2009;20(7):1641-1649.
64. Muntinghe FL, Vegter S, Verduijn M, et al. Using a genetic, observational study as a strategy to estimate the potential costeffectiveness of pharmacological CCR5 blockade in dialysis patients. Pharmacogenet Genomics. 2011;21(7):417-425.
65. Smith GD, Ebrahim S. Mendelian randomization: prospects, potentials, and limitations. Int J Epidemiol. 2004;33(1):30-42.
66. Sarwar N, Butterworth AS, Freitag DF, et al. IL6R Genetics Consortium Emerging Risk Factors Collaboration. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet. 2012; 379(9822):1205-1213.
67. Hingorani AD, Casas JP; Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet. 2012;379(9822):1214-1224.
68. Board P, Coggan M, Johnston P, Ross V, Suzuki T, Webb G. Genetic heterogeneity of the human glutathione transferases: a complex of gene families. Pharmacol Ther. 1990;48(3):357-369.
69. Ryberg D, Skaug V, Hewer A, et al. Genotypes of glutathione transferase M1 and P1 and their significance for lung DNA adduct levels and cancer risk. Carcinogenesis. 1997;18(7):1285-1289.
70. Lin YS, Hung SC, Wei YH, Tarng DC. GST M1 polymorphism associates with DNA oxidative damage and mortality among hemodialysis patients. J Am Soc Nephrol. 2009;20(2): 405-415.
71. Nordfors L, Lindholm B, Stenvinkel P. End-stage renal disease: not an equal opportunity disease: the role of genetic polymorphisms. J Intern Med. 2005;258(1):1-12.
72. Stenvinkel P. Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease. J Intern Med. 2010;268(5):456-467.
73. Hunter DJ. Gene-environment interactions in human diseases. Nat Rev Genet. 2005;6(4):287-298.
74. Davey Smith G, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32(1): 1-22.
75. Smilde TD, Zuurman MW, Hillege HL, et al. Renal function dependent association of AGTR1 polymorphism (A1166C) and electrocardiographic left-ventricular hypertrophy. Am J Hypertens. 2007;20(10):1097-1103.
76. Smilde TD, Asselbergs FW, Hillege HL, et al. Mild renal dysfunction is associated with electrocardiographic left ventricular hypertrophy. Am J Hypertens. 2005;18(3):342-347.
77. Kuznetsova T, Staessen JA, Thijs L, et al. European Project On Genes in Hypertension (EPOGH) Investigators. Left ventricular mass in relation to genetic variation in angiotensin II receptors, renin system genes, and sodium excretion. Circulation. 2004;110(17):2644-2650.
78. Ohishi M, Rakugi H, Ogihara T. Association between a deletion polymorphism of the angiotensin-convertingenzyme gene and left ventricular hypertrophy. N Engl J Med. 1994;331(16):1097-1098.
79. Schunkert H. Controversial association of left ventricular hypertrophy and the ACE I/D polymorphism: is the mist clearing up? Nephrol Dial Transplant. 1998;13(5):1109-1112.
80. Brewster UC, Perazella MA. The renin-angiotensinaldosterone system and the kidney: effects on kidney disease. Am J Med. 2004;116(4):263-272.
81. van der Kleij FG, Schmidt A, Navis GJ, et al. Angiotensin converting enzyme insertion/deletion polymorphism and short-term renal response to ACE inhibition: role of sodium status. Kidney Int Suppl. 1997;63:S23-S26.
82. van der Kleij FG, de Jong PE, Henning RH, de Zeeuw D, Navis G. Enhanced responses of blood pressure, renal function, and aldosterone to angiotensin I in the DD genotype are blunted by low sodium intake. J Am Soc Nephrol. 2002;13(4):1025-1033.
83. The Secretary's Advisory Committee on Genetic Testing. Enhancing the oversight of genetic tests: recommendations of the SACGT. 2000. Available at: http://oba.od.nih.gov/oba/sacgt/reports/oversight_report.pdf. Accessed April 3, 2012.
84. Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex diseases. Nature. 2009;461(7265): 747-753.
85. Durbin RM, Altshuler DL, Durbin RM, et al. 1000 Genomes Project Consortium. A map of human genome variation from population-scale sequencing. Nature. 2010;467(7319): 1061-1073.
86. 1000 Genomes: a deep catalog of human genetic variation. Available at: http://www.1000genomes.org/. Accessed April 3, 2012.
87. Xing C, Cohen JC, Boerwinkle E. A weighted false discovery rate control procedure reveals alleles at FOXA2 that influence fasting glucose levels. Am J Hum Genet. 2010;86(3):440-446.
88. Williams GC. Pleiotropy, natural selection, and the evolution of senescence. Evolution. 1957;11(4):398-411.
89. He X, Zhang J. Toward a molecular understanding of pleiotropy. Genetics. 2006;173(4):1885-1891.
90. Otto SP. Two steps forward, one step back: the pleiotropic effects of favoured alleles. Proc Biol Sci. 2004;271(1540):705-714.
91. Blagosklonny MV. Why men age faster but reproduce longer than women: mTOR and evolutionary perspectives. Aging (Albany NY). 2010;2(5):265-273.